Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Chemosphere ; 358: 142222, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38714249

RESUMEN

In this study, neural networks and support vector regression (SVR) were employed to predict the degradation over three pharmaceutically active compounds (PhACs): Ibuprofen (IBP), diclofenac (DCF), and caffeine (CAF) within a stirred reactor featuring a flotation cell with two non-concentric ultraviolet lamps. A total of 438 datapoints were collected from published works and distributed into 70% training and 30% test datasets while cross-validation was utilized to assess the training reliability. The models incorporated 15 input variables concerning reaction kinetics, molecular properties, hydrodynamic information, presence of radiation, and catalytic properties. It was observed that the Support Vector Regression (SVR) presented a poor performance as the ε hyperparameter ignored large error over low concentration levels. Meanwhile, the Artificial Neural Networks (ANN) model was able to provide rough estimations on the expected degradation of the pollutants without requiring information regarding reaction rate constants. The multi-objective optimization analysis suggested a leading role due to ozone kinetic for a rapid degradation of the contaminants and most of the results required intensification with hydrogen peroxide and Fenton process. Although both models were affected by accuracy limitations, this work provided a lightweight model to evaluate different Advanced Oxidation Processes (AOPs) by providing general information regarding the process operational conditions as well as know molecular and catalytic properties.


Asunto(s)
Diclofenaco , Peróxido de Hidrógeno , Ibuprofeno , Aprendizaje Automático , Redes Neurales de la Computación , Diclofenaco/química , Peróxido de Hidrógeno/química , Ibuprofeno/química , Cinética , Contaminantes Químicos del Agua/química , Contaminantes Químicos del Agua/análisis , Cafeína/química , Oxidación-Reducción , Preparaciones Farmacéuticas/química , Preparaciones Farmacéuticas/análisis , Ozono/química , Máquina de Vectores de Soporte , Análisis Costo-Beneficio , Rayos Ultravioleta , Catálisis , Fotólisis
3.
Clin. transl. oncol. (Print) ; 15(7): 503-508, jul. 2013. ilus
Artículo en Inglés | IBECS | ID: ibc-127462

RESUMEN

The arrival of targeted therapies has presented both a conceptual and a practical challenge in the treatment of patients with advanced non-small cell lung carcinomas (NSCLCs). The relationship of these treatments with specific histologies and predictive biomarkers has made the handling of biopsies the key factor for success. In this study, we highlight the balance between precise histological diagnosis and the practice of conducting multiple predictive assays simultaneously. This can only be achieved where there is a commitment to multidisciplinary working by the tumor board to ensure that a sensible protocol is applied. This proposal for prioritizing samples includes both recent technological advances and the some of the latest discoveries in the molecular classification of NSCLCs (AU)


Asunto(s)
Humanos , Adenocarcinoma/patología , Carcinoma de Pulmón de Células no Pequeñas/patología , Neoplasias Pulmonares/patología , Biomarcadores de Tumor/metabolismo , Adenocarcinoma/metabolismo , Adenocarcinoma/terapia , Carcinoma de Pulmón de Células no Pequeñas/metabolismo , Carcinoma de Pulmón de Células no Pequeñas/terapia , Diferenciación Celular , Neoplasias Pulmonares/metabolismo , Neoplasias Pulmonares/terapia , Terapia Molecular Dirigida
4.
Clin Transl Oncol ; 15(7): 503-8, 2013 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-23359174

RESUMEN

The arrival of targeted therapies has presented both a conceptual and a practical challenge in the treatment of patients with advanced non-small cell lung carcinomas (NSCLCs). The relationship of these treatments with specific histologies and predictive biomarkers has made the handling of biopsies the key factor for success. In this study, we highlight the balance between precise histological diagnosis and the practice of conducting multiple predictive assays simultaneously. This can only be achieved where there is a commitment to multidisciplinary working by the tumor board to ensure that a sensible protocol is applied. This proposal for prioritizing samples includes both recent technological advances and the some of the latest discoveries in the molecular classification of NSCLCs.


Asunto(s)
Adenocarcinoma/patología , Biomarcadores de Tumor/metabolismo , Carcinoma de Pulmón de Células no Pequeñas/patología , Neoplasias Pulmonares/patología , Adenocarcinoma/metabolismo , Adenocarcinoma/terapia , Adenocarcinoma del Pulmón , Carcinoma de Pulmón de Células no Pequeñas/metabolismo , Carcinoma de Pulmón de Células no Pequeñas/terapia , Diferenciación Celular , Humanos , Neoplasias Pulmonares/metabolismo , Neoplasias Pulmonares/terapia , Terapia Molecular Dirigida
5.
Invest New Drugs ; 31(1): 14-9, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-22669334

RESUMEN

A high throughput screening for anticancer activity of FDA approved drugs identified mycophenolic acid (MPA), an inhibitor of inositol monophosphate dehydrogenase (IMPDH) as an active agent with an antiangiogenesis mode of action. Exposure of pancreatic cancer cell lines to MPA resulted in growth inhibition and reduced the expression of VEGF that was reversed by supplementing the media with guanosine supporting and IMPDH-dependant mechanism. In preclinical in vivo study, MPA showed a moderate inhibition of tumor growth in a panel of 6 human derived pancreatic cancer xenografts but reduced the expression of VEGF. To investigate the effects of MPA in human pancreatic cancer, a total of 12 patients with resectable pancreatic cancer (PDA) received increasing doses of mycophenolate mofetil (MMF) in cohorts of 6 patients each from 5-15 days prior to surgical resection. Treatment was well tolerated with one episode of grade 1 muscle pain, one episode of grade 2 lymphopenia (2 gr/day dose) and one episode of grade 2 elevantion in LFT (all in the 2 gr./day dose). Patients recovered from surgery uneventfully with no increased post-operative complications. Assessment of CD31, VEGF, and TUNEL in resected specimens compared to a non treated control of 6 patients showed no significant variations in any of the study endpoints. In conclusion, this study shows the feasibility of translating a preclinical observation to the clinical setting and to explore a drug mechanism of action in patients. MPA, however, did not show any hints of antiangiogenesis of anticancer clinical activity questioning if this agent should be further developed in PDA.


Asunto(s)
Carcinoma Ductal Pancreático/tratamiento farmacológico , Inmunosupresores/uso terapéutico , Ácido Micofenólico/análogos & derivados , Neoplasias Pancreáticas/tratamiento farmacológico , Anciano , Animales , Carcinoma Ductal Pancreático/metabolismo , Carcinoma Ductal Pancreático/patología , Línea Celular Tumoral , Femenino , Guanosina Trifosfato/metabolismo , Humanos , Inmunosupresores/sangre , Inmunosupresores/farmacología , Masculino , Ratones , Persona de Mediana Edad , Ácido Micofenólico/sangre , Ácido Micofenólico/farmacología , Ácido Micofenólico/uso terapéutico , Neoplasias Pancreáticas/metabolismo , Neoplasias Pancreáticas/patología , Resultado del Tratamiento , Carga Tumoral/efectos de los fármacos , Ensayos Antitumor por Modelo de Xenoinjerto
6.
Br J Cancer ; 107(2): 345-51, 2012 Jul 10.
Artículo en Inglés | MEDLINE | ID: mdl-22713664

RESUMEN

BACKGROUND: KRAS mutation testing is required to select patients with metastatic colorectal cancer (CRC) to receive anti-epidermal growth factor receptor antibodies, but the optimal KRAS mutation test method is uncertain. METHODS: We conducted a two-site comparison of two commercial KRAS mutation kits - the cobas KRAS Mutation Test and the Qiagen therascreen KRAS Kit - and Sanger sequencing. A panel of 120 CRC specimens was tested with all three methods. The agreement between the cobas test and each of the other methods was assessed. Specimens with discordant results were subjected to quantitative massively parallel pyrosequencing (MPP). DNA blends were tested to determine detection rates at 5% mutant alleles. RESULTS: Reproducibility of the cobas test between sites was 98%. Six mutations were detected by cobas that were not detected by Sanger, and five were confirmed by MPP. The cobas test detected eight mutations which were not detected by the therascreen test, and seven were confirmed by MPP. Detection rates with 5% mutant DNA blends were 100% for the cobas and therascreen tests and 19% for Sanger. CONCLUSION: The cobas test was reproducible between sites, and detected several mutations that were not detected by the therascreen test or Sanger. Sanger sequencing had poor sensitivity for low levels of mutation.


Asunto(s)
Neoplasias Colorrectales/genética , Mutación , Proteínas Proto-Oncogénicas/genética , Proteínas ras/genética , Adulto , Anciano , Anciano de 80 o más Años , Neoplasias Colorrectales/patología , Femenino , Formaldehído , Humanos , Masculino , Persona de Mediana Edad , Proteínas Proto-Oncogénicas p21(ras) , Reproducibilidad de los Resultados , Análisis de Secuencia de ADN , Fijación del Tejido
7.
J Pathol ; 214(3): 347-56, 2008 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-17992665

RESUMEN

The development of targeted therapies creates a need to discriminate tumours accurately by their histological and genetic characteristics. Here, we aim to identify gene expression profiles and single markers that recapitulate the pathological and genetic background of non-small cell lung cancer (NSCLC). We performed cDNA microarray analysis on a series of 69 NSCLCs, with known mutation status for important genes, and six normal lung tissues. Unsupervised cluster analysis segregated normal lungs from lung tumours and lung tumours according to their histopathology and the presence of EGFR mutations. Several transcripts were highly overexpressed (by approximately 20 times) in squamous cell carcinomas (SCCs) relative to adenocarcinomas (ACs) and confirmed by immunohistochemistry in an independent cohort of 75 lung tumours. Expression of 13 genes constituted the most prominent hallmarks of EGFR-mutant tumours, including increased levels of proline dehydrogenase (PRODH) and down-regulation of X-box binding protein 1 (XBP1). No genes were differentially expressed, with a fold change >or= 4 or

Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas/genética , Perfilación de la Expresión Génica , Marcadores Genéticos , Neoplasias Pulmonares/genética , Análisis de Secuencia por Matrices de Oligonucleótidos , Adenocarcinoma/genética , Carcinoma de Células Escamosas/genética , Estudios de Casos y Controles , Fosfatidilinositol 3-Quinasa Clase I , Análisis por Conglomerados , Receptores ErbB/genética , Amplificación de Genes , Genes ras , Humanos , Inmunohistoquímica , Hibridación Fluorescente in Situ , Mutación , Fosfatidilinositol 3-Quinasas/genética
8.
Cienc. ginecol ; 6(1): 24-26, ene. 2002. ilus
Artículo en Es | IBECS | ID: ibc-14246

RESUMEN

Se presenta el caso de una gestante de 33 semanas con rotura prematura de membranas en el que se sospechó un prolapso de cordón gracias a las características de cardiotocograma basal que presentaba deceleraciones variables. (AU)


Asunto(s)
Adulto , Embarazo , Femenino , Humanos , Recién Nacido , Cardiotocografía/métodos , Cordón Umbilical , Enfermedades Fetales/diagnóstico , Rotura Prematura de Membranas Fetales/fisiopatología , Prolapso , Cesárea
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA